KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Total Debt (2016 - 2025)

Pacira BioSciences has reported Total Debt over the past 14 years, most recently at $372.2 million for Q4 2025.

  • Quarterly results put Total Debt at $372.2 million for Q4 2025, down 36.41% from a year ago — trailing twelve months through Dec 2025 was $372.2 million (down 36.41% YoY), and the annual figure for FY2025 was $372.2 million, down 36.41%.
  • Total Debt for Q4 2025 was $372.2 million at Pacira BioSciences, down from $376.7 million in the prior quarter.
  • Over the last five years, Total Debt for PCRX hit a ceiling of $685.7 million in Q4 2021 and a floor of $109.8 million in Q2 2024.
  • Median Total Debt over the past 5 years was $292.5 million (2022), compared with a mean of $278.3 million.
  • Biggest five-year swings in Total Debt: crashed 69.52% in 2023 and later skyrocketed 372.63% in 2024.
  • Pacira BioSciences' Total Debt stood at $685.7 million in 2021, then tumbled by 58.48% to $284.7 million in 2022, then plummeted by 56.5% to $123.8 million in 2023, then surged by 372.63% to $585.3 million in 2024, then plummeted by 36.41% to $372.2 million in 2025.
  • The last three reported values for Total Debt were $372.2 million (Q4 2025), $376.7 million (Q3 2025), and $300.2 million (Q2 2025) per Business Quant data.